Are you or your loved ones suffering from recurrent glioblastoma?

You may be eligible to participate in a recurrent glioblastoma clinical trial.

Are you or your loved ones suffering from recurrent glioblastoma? You may be eligible to participate in a recurrent glioblastoma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Glioblastoma (GBM) and H3 K27M-mutant Glioma
NCT02525692 | Phase 2 | Interventional
What you may receive

Study related treatment at no cost

Oncoceutics Inc
Sponsored by
Oncoceutics Inc

Are you or your loved ones suffering from recurrent glioblastoma?

You may be eligible to participate in a recurrent glioblastoma clinical trial.

Are you or your loved ones suffering from recurrent glioblastoma? You may be eligible to participate in a recurrent glioblastoma clinical trial.

Recruiting

Male & Female

18 +

years old

ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients. This clinical trial will enroll patients with recurrent glioblastoma or recurrent WHO Grade IV gliomas with the H3 K27M mutation.

Where you'll go

Selected location

Massachusetts General Hospital

Massachusetts General Hospital Change

15 Parkman Street, Boston, MA, USA 02114

Isabel Arrillaga, MD, PhD 617-726-2000

Get directions | Learn more

Available locations
Dana Farber Cancer Institute

Dana Farber Cancer Institute

Recruiting 450 Brookline Avenue, Boston, MA, USA 02115

Miami Cancer Institute

Miami Cancer Institute

Recruiting 8900 North Kendall Drive, Miami, FL, USA 33176

Interested in participating?

Selected location

Massachusetts General Hospital

15 Parkman Street, Boston, MA, USA 02114

Isabel Arrillaga, MD, PhD 617-726-2000


By clicking the button, you agree to the Terms and Privacy Policy.

Sign up now